Icosapent ethyl (Vazkepa®). HTA ID: 23006

Assessment Status Full HTA submission received from Applicant
HTA ID 23006
Drug Icosapent ethyl
Brand Vazkepa®
Indication Icosapent ethyl (Vazkepa®) is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (?150 mg/dL [?1.7 mmol/L] and established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.
Assessment Process
Rapid review commissioned 10/02/2023
Rapid review completed 10/03/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of icosapent ethyl compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/03/2023
Pre-submission consultation with Applicant 20/06/2023
Full submission received from Applicant 01/11/2023